British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for pancreatic cancer.
from Latest News https://ift.tt/2IyftH4
AstraZeneca's Lynparza meets main goal of late-stage cancer study
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment